ReviewDrug development research2021

CB2 receptor-selective agonists as candidates for targeting infection, inflammation, and immunity in SARS-CoV-2 infections.

M F Nagoor Meeran et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.